XERS Xeris Pharmaceuticals Inc

Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations.

As of 12/06/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/21/2018
Outstanding shares:  124,708,935
Average volume:  2,198,334
Market cap:   $254,406,227
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    98422E103
ISIN:        US98422L1070
Sedol:      BLR7H87
Valuation   (See tab for details)
PE ratio:   -2.67
PB ratio:   6.72
PS ratio:   7.23
Return on equity:   3,811.13%
Net income %:   -266.73%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy